Scientists discuss the use of NMR to analyze the antiviral drug Azidothymidine AZT, a medication currently used to prevent and treat HIV/AIDS.

Lead optimization in drug discovery has changed significantly during the last few years. Structural information on ligand-protein complexes, at atomic resolution, is considered to be extremely important to improve binding affinity. Moreover, the nature and energy of conformational changes of the free ligand in solution, can drive the binding recognition procedure, improving binding efficacy overall.

In this Bruker webinar, Dr. Armando Navarro will discuss the analysis of the antiviral drug Azidothymidine AZT (or Zidovudine ZDT). This compound is used as antiretroviral medication to prevent and treat HIV/AIDS and how to combine different NMR observables (NOE, J-couplings, chemical shifts…) for a more accurate conformational analysis.

Presenters

Professor
Federal University of Pernambuco

Armando Navarro got his PhD. in chemistry at the University of Santiago de Compostela. After his post-doctoral studies in the Institut für Organische Chemie he joined the University of Santiago de Compostela where he worked in the development of NMR oriented software. He moved later to the University of Vigo and in 2014 he moved to the University Federal of Pernambuco where he holds currently a full professorship. His research is focused in the development of computational strategies and materials applied the structural elucidation of organic compounds.

Solution Developer & Product Manager
Bruker BioSpin

Matteo Pennestri obtained his Ph.D. in Biophysical methods at the University of Tor Vergata Rome (collaboration with Merck Sharp and Dohme). Then he moved as NMR spectroscopist in the pharmaceutical industry (MSD and EISAI). After experiencing the pharma sector, he joined as application scientist Agilent Technologies first (ex. Varian) and Bruker afterwards. Recently he joined the Bruker Pharma unit as NMR specialist and product manager.

Production Partner

Bruker Corporation

Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.

Additional Content From Bruker Corporation

Related Content

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.